Journey Medical (DERM) Expected to Announce Quarterly Earnings on Wednesday

Journey Medical (NASDAQ:DERM) is anticipated to post its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $18.8630 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

Journey Medical Trading Up 0.7%

NASDAQ DERM opened at $7.50 on Wednesday. The company’s fifty day simple moving average is $8.15 and its 200-day simple moving average is $7.84. The stock has a market cap of $249.45 million, a P/E ratio of -21.43 and a beta of 0.81. Journey Medical has a 52 week low of $5.23 and a 52 week high of $9.56. The company has a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.75.

Institutional Trading of Journey Medical

A number of hedge funds and other institutional investors have recently modified their holdings of DERM. Bank of America Corp DE increased its position in Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after purchasing an additional 4,048 shares during the period. Raymond James Financial Inc. bought a new position in shares of Journey Medical in the 2nd quarter valued at about $36,000. JPMorgan Chase & Co. bought a new position in shares of Journey Medical in the 2nd quarter valued at about $41,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Journey Medical during the 2nd quarter worth approximately $48,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Journey Medical during the third quarter worth approximately $61,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.17.

About Journey Medical

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.